Condition
Immune-mediated Hepatitis
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting4
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07663422Phase 2Not Yet RecruitingPrimary
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
NCT04476563RecruitingPrimary
Checkpoint Inhibitor-induced Liver Injury
NCT06470997RecruitingPrimary
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
NCT07167251Recruiting
Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
NCT05484908Not ApplicableRecruitingPrimary
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
Showing all 5 trials